Sep 06, 2023 / 12:50PM GMT
Yigal Dov Nochomovitz - Citigroup Inc., Research Division - Director
So welcome, everyone. I'm Yigal Nochomovitz, one of the biotech analysts at Citi. My pleasure to have with me my colleague, Samantha Semenkow, recently rejoined Citi as a senior analyst. This is the rare neuro panel, and it's my pleasure to have with me two distinguished CEOs in the space. Carole Ben-Maimon, the CEO of Lamar and Emil Kakkis, the CEO of Ultragenyx. So welcome, both of you. Thank you very much for taking the time. And maybe just to start out, if you could just give a very brief 2- or 3-minute overview of some of the rare neurology programs that you're focused on. And then from there, we can move into some more thematic questions related to development of drugs for rare neurology. So Emil, you want to start?
Emil D. Kakkis - Ultragenyx Pharmaceutical Inc. - Founder, President, CEO & Director
Okay. Sure. Good morning, everyone. So I'm Emil Kakkis, CEO of Ultragenyx. And we've been formed for about 13 years ago and have been building a portfolio of products in the [born] errors,
Ultragenyx Pharmaceutical Inc at Citi BioPharma Conference Transcript
Sep 06, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers